de Jong Frank Jan, Peeters Robin P, den Heijer Tom, van der Deure Wendy M, Hofman Albert, Uitterlinden André G, Visser Theo J, Breteler Monique M B
Department of Epidemiology, Biostatistics, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands.
J Clin Endocrinol Metab. 2007 Feb;92(2):636-40. doi: 10.1210/jc.2006-1331. Epub 2006 Nov 14.
Thyroid function has been related to Alzheimer disease (AD) and neuroimaging markers thereof. Whether thyroid dysfunction contributes to or results from developing AD remains unclear. Variations in the deiodinase type 1 (DIO1) and type 2 (DIO2) genes that potentially alter thyroid hormone bioactivity may help in elucidating the role of thyroid function in AD.
We investigated the association of recently identified polymorphisms in the DIO1 (D1a-C/T, D1b-A/G) and DIO2 (D2-ORFa-Gly3Asp, D2-Thr92Ala) genes with circulating thyroid parameters and early neuroimaging markers of AD.
The Rotterdam Scan Study is a population-based cohort study among 1,077 elderly individuals aged 60-90 yr.
DIO1 and DIO2 polymorphisms and serum TSH, free T4, T3, and reverse T3 (rT3) levels were determined in 995 nondemented elderly, including 473 persons with assessments of hippocampal and amygdalar volume on brain magnetic resonance imaging.
Carriers of the D1a-T allele had higher serum free T4 and rT3, lower T3, and lower T3/rT3. The D1b-G allele was associated with higher serum T3 and T3/rT3. The DIO2 variants were not associated with serum thyroid parameters. No associations were found with hippocampal or amygdalar volume.
This is the first study to report an association of D1a-C/T and D1b-A/G polymorphisms with iodothyronine levels in the elderly. Polymorphisms in the DIO1 and DIO2 genes are not associated with early magnetic resonance imaging markers of AD. This suggests that the previously reported association between iodothyronine levels and brain atrophy reflects comorbidity or nonthyroidal illness rather than thyroid hormones being involved in developing AD.
甲状腺功能与阿尔茨海默病(AD)及其神经影像学标志物相关。甲状腺功能障碍是导致AD发生还是由AD引起尚不清楚。1型脱碘酶(DIO1)和2型脱碘酶(DIO2)基因的变异可能会改变甲状腺激素的生物活性,这可能有助于阐明甲状腺功能在AD中的作用。
我们研究了DIO1基因(D1a-C/T、D1b-A/G)和DIO2基因(D2-ORFa-Gly3Asp、D2-Thr92Ala)中最近发现的多态性与循环甲状腺参数及AD早期神经影像学标志物之间的关联。
鹿特丹扫描研究是一项针对1077名60至90岁老年人的基于人群的队列研究。
在995名非痴呆老年人中测定了DIO1和DIO2基因多态性以及血清促甲状腺激素(TSH)、游离甲状腺素(free T4)、三碘甲状腺原氨酸(T3)和反三碘甲状腺原氨酸(rT3)水平,其中473人接受了脑磁共振成像对海马体和杏仁核体积的评估。
D1a-T等位基因携带者的血清游离T4和rT3水平较高,T3水平较低,T3/rT3也较低。D1b-G等位基因与较高的血清T3和T3/rT3相关。DIO2基因变异与血清甲状腺参数无关。未发现与海马体或杏仁核体积有关联。
这是第一项报道D1a-C/T和D1b-A/G多态性与老年人甲状腺素水平相关的研究。DIO1和DIO2基因的多态性与AD早期磁共振成像标志物无关。这表明先前报道的甲状腺素水平与脑萎缩之间的关联反映的是合并症或非甲状腺疾病,而非甲状腺激素参与AD的发生。